Success Metrics

Clinical Success Rate
92.6%

Based on 25 completed trials

Completion Rate
93%(25/27)
Active Trials
0(0%)
Results Posted
16%(4 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_2
2
6%
Ph phase_3
2
6%
Ph phase_4
15
42%
Ph early_phase_1
3
8%
Ph phase_1
4
11%
Ph not_applicable
7
19%

Phase Distribution

7

Early Stage

2

Mid Stage

17

Late Stage

Phase Distribution33 total trials
Early Phase 1First-in-human
3(9.1%)
Phase 1Safety & dosage
4(12.1%)
Phase 2Efficacy & side effects
2(6.1%)
Phase 3Large-scale testing
2(6.1%)
Phase 4Post-market surveillance
15(45.5%)
N/ANon-phased studies
7(21.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.2%

25 of 29 finished

Non-Completion Rate

13.8%

4 ended early

Currently Active

0

trials recruiting

Total Trials

36

all time

Status Distribution
Active(1)
Completed(25)
Terminated(4)
Other(6)

Detailed Status

Completed25
unknown6
Terminated2
Withdrawn2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
36
Active
0
Success Rate
92.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (9.1%)
Phase 14 (12.1%)
Phase 22 (6.1%)
Phase 32 (6.1%)
Phase 415 (45.5%)
N/A7 (21.2%)

Trials by Status

completed2569%
not_yet_recruiting13%
terminated26%
unknown617%
withdrawn26%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT07348172Early Phase 1

Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings

Not Yet Recruiting
NCT01701258Phase 1

An Investigation of Early Life Stress and Depression

Completed
NCT04128683Early Phase 1

Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

Completed
NCT04876521Phase 4

Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression

Completed
NCT01972711Phase 1

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

Completed
NCT05822713Phase 3

A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.

Unknown
NCT04954365

Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment

Withdrawn
NCT04341467Not Applicable

Amisulpride Treatment for BPSD in AD Patients

Unknown
NCT01498770

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

Completed
NCT04533724Early Phase 1

Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia

Unknown
NCT04446234Phase 4

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building

Unknown
NCT01446328Phase 4

Bergen Psychosis Project 2 - The Best Intro Study

Completed
NCT01609153Phase 4

Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy

Completed
NCT03802838Phase 4

Clinical Evaluation of Acupuncture Treatment for Negative Symptoms of Schizophrenia

Unknown
NCT02307396Phase 4

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Completed
NCT01253421Phase 1

The Effects of Dopamine on Reward Processing

Completed
NCT02051387Phase 1

Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT01555814Not Applicable

Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen

Completed
NCT01154829Not Applicable

Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
36